Introduction

The increasing prevalence of chronic kidney disease (CKD), with its associated high annual rates of mortality and cardiovascular complications (1, 2), is a major public health problem. In Japan, clinical practice guidelines established by the Japanese Society of Nephrology predict that 18.7% of adults have CKD, which is defined as kidney damage or a glomerular filtration rate (GFR) <60 mL/min/ 1.73 m 2 for at least three months regardless of cause (3), and 4.1% have moderate or severe CKD (4). Identifying and treating risk factors for early CKD in the population may prevent or delay adverse outcomes. Metabolic syndrome (MetS), or a clustering of cardiovascular risk factors, such as insulin resistance, hypertension, glucose intolerance, hypertriglyceridemia, and low highdensity lipoprotein cholesterol (HDL-C) concentrations, is a major worldwide public health problem. MetS is quite com-
Materials and Methods
Subjects
Participants were recruited at the time of their annual health examination in a rural town: Nomura-cho, Seiyo-city, which is located in Ehime prefecture, Japan had a total population of 11, 136 
Metabolic syndrome
We applied condition-specific cutoff points for MetS based on the modified guidelines for diagnosis of MetS in Japan (13 (Fig. 1) . T a b l e 1 . Ch a r a c t e r i s t i c s o f t h e S t u d y P a r t i c i p a n t s wi t h a n d wi t h o u t t h e Me t a b o l i (18) , and those with MetS had a higher prevalence of CKD, defined as an eGFR of <60 or albuminuria, than those without the syndrome (27.6% and 14.0%, respectively) (19) . Moreover, Ninomiya et al (20) (19, 21) . However, these differences in the prevalence might have been partly due to the differences in the definitions used for the MetS and CKD (22) . These findings suggest that the MetS directly contributes to the increased risk of CKD.
MetS that was defined using the criteria of International Diabetes Federation (IDF) (16), and those with MetS had a higher prevalence of CKD, defined as an eGFR of <60 or albuminuria, than those without the syndrome (15.4% and 8.3%, respectively) (17). In the Takahata study that was performed in Yamagata prefecture, Japan, 16.5% of the total participants aged from 40 to 87 years had MetS that was de-
T a b l e 2 . e GF R a n d t h e P r o p o r t i o n o f P a r t i c i p a n t s wi t h Ch r o n i c Ki d n e y Di s e a s e a mo n g T h o s e wi t h a n d wi t h o u t E a c h Co mp o n e n t o f t h e Me t a b o l i c S y n d r o me fined using the modified National Cholesterol Education Program (NCEP) Adult Treatment Panel III (ATP III) guidelines criteria
Obesity is a significant risk factor for developing CKD and proteinuria (23) (24) (25) g u r e 1 . P r e v a l e n c e o f c h r o n i c k i d n e y d i s e a s e a n d e s t i ma t e d g l o me r u l a r f i l t r a t i o n r a t e ( me a n ±  s t a n d a r d d e v i a t i o n ) b y n u mb e r o f t h e me t a b o l i c s y n d r o me c o mp o n e n (26) , which can contribute to CKD (27, 28) . In Japan, diabetes has become the leading cause of new onset dialysis (29 T a b l e 4 . Cr u d e a n d Mu l t i v a r i a t e -a d j u s t 
T a b l e 3 . Re l a t i o n s h i p b e t we e n Va r i o u s Ri s k F a c t o r s I n c l u d i n g Me t a b o l i c S y n d r o me a n d E s t i ma t e d Gl o me r u l a r F i l t r a t i o n Ra t e .
F i
e d Od d s Ra t i o s o f Ch r o n i c Ki d n e y Di s e a s e As s o c ia t e d wi t h I n d i v i d u a l a n d S e v e r a l Co mp o n e n t s o f t h e Me t a b o l i c S y n d r o me
(i.e., C-reactive protein) (30) , hyperhomocystinemia (31) , increased oxidative stress (32) , hyperlipidemia (5) , hyperleptinemia (33) , increased sympathetic activity (34) , hyperfiltration caused by hyperinsulinemia (35) , activation of the renin-angiotensin system (36) , and cytokine expression (37 (40) . The mechanisms whereby lipids contribute to renal injury are uncertain, but glomerulosclerosis and atherosclerosis seem to share common mechanisms (41) .
Hypertension contributes to the development of renal injury and end-stage renal disease (42, 43 
